10-Q: Co-Diagnostics Q1 2026 Results: Increased R&D, Net Loss Widens

Co-Diagnostics reports a wider net loss for Q1 2026 due to increased R&D spending and lower other income, despite a rise in product revenue.

Summary

• Co-Diagnostics reported a net loss of $9.14 million for the three months ended March 31, 2026, an increase from the $7.53 million net loss in the same period of 2025.
• Total revenue for the quarter was $0.15 million, up from $0.05 million in the prior year's quarter.
• Cost of revenue increased significantly to $0.19 million from $0.02 million.
• Operating expenses rose to $9.16 million from $8.58 million, primarily driven by increased research and development (R&D) costs related to the Co-Dx PCR platform and higher legal expenses.
• Sales and marketing expenses decreased to $0.47 million from $0.66 million, while general and administrative expenses fell to $2.50 million from $2.77 million.
• R&D expenses increased to $5.93 million from $4.87 million.
• Other income decreased to $0.07 million from $1.03 million, mainly due to changes in contingent consideration liabilities and lower realized investment gains.
• The company had $8.23 million in cash and cash equivalents as of March 31, 2026.
• Net cash used in operating activities was $7.85 million, a slight improvement from $8.75 million in the prior year.
• Net cash provided by financing activities was $4.33 million, primarily from at-the-market (ATM) equity offerings.
• The company continues to face substantial doubt regarding its ability to continue as a going concern, dependent on obtaining additional financing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the widening net loss, increased R&D expenses without immediate revenue generation, and the ongoing going concern uncertainty, despite some positive revenue growth and financing activities.

Positives

• Product revenue increased to $0.15 million for the three months ended March 31, 2026, from $0.05 million in the same period of 2025.
• Net cash used in operating activities decreased to $7.85 million from $8.75 million.
• The company secured $4.33 million in net cash from financing activities through at-the-market equity offerings.
• Favorable ruling received in litigation with Hukui Technology, Inc.
• Settlement reached with Pantheon International Advisors Ltd. for $140,000, resolving all disputes.

Negatives

• Net loss widened to $9.14 million from $7.53 million.
• Cost of revenue increased significantly to $0.19 million from $0.02 million.
• Operating expenses increased to $9.16 million from $8.58 million.
• Other income decreased substantially to $0.07 million from $1.03 million.
• Substantial doubt exists about the company's ability to continue as a going concern.
• The company withdrew its 510(k) submission for the Co-Dx PCR Pro instrument and COVID-19 test due to discussions with the FDA regarding analytical approach for detecting potential degradation.

Risks

• The company's ability to continue as a going concern is dependent on its ability to obtain necessary financing and generate profitable operations.
• There is substantial doubt about the company's ability to continue as a going concern for the next 12 months.
• The company withdrew its 510(k) submission for the Co-Dx PCR Pro instrument and COVID-19 test, requiring additional development and clinical validation for resubmission.
• The Co-Dx PCR platform is subject to FDA review and is not yet available for sale.
• There is no guarantee that the Co-Dx PCR platform will receive necessary regulatory approvals or be successfully commercialized.
• The company faces significant customer concentration, with five customers accounting for approximately 84% of product revenue in Q1 2026.
• Two customers accounted for approximately 49% of accounts receivable at March 31, 2026.
• The company is a defendant in a class action lawsuit alleging overstatement of demand for its Logix Smart COVID-19 test.
• The company is also a party to a civil action based on breach of contract claims.
• While the company believes the lawsuits are without merit, an unfavorable outcome could be material to its results of operations.

Future Outlook

The company anticipates continuing to generate operating losses and use cash in operations in the near term. Future investment capital is expected to come from additional issuances of common stock or other equity-based securities, or debt financing. The company's ability to obtain additional financing is not assured and may not be available on favorable terms, and any equity financing is likely to be dilutive. The company is focusing development efforts on the Co-Dx PCR Flu A/B, COVID-19, RSV multiplex test (ABCR) due to current clinical demand.

Management Comments

• Management determined that the capital and time required to resubmit the COVID-19 test for 510(k) clearance would be more effectively deployed toward development and clinical validation of the Co-Dx PCR Flu A/B, COVID-19, RSV multiplex test (ABCR).
• Management believes that a multiplex test targeting influenza A/B, COVID-19, and RSV better aligns with current clinical demand for comprehensive upper respiratory infection testing in point-of-care settings.
• Management believes that owning their own platform allows them to accomplish innovation faster and more economically than some competitors, allowing for significant margins while still positioning themselves as a low-cost provider.
• Management believes that the proprietary test design system and reagents, along with the Co-Primers technology, are ideally suited for a variety of applications where specificity is key to optimal results.

Industry Context

StockSavvy.ai notes that Co-Diagnostics' Q1 2026 results reflect the ongoing challenges in the molecular diagnostics market, particularly the shift in focus from single-target COVID-19 tests to multiplexed respiratory panels. The increased R&D spending on the Co-Dx PCR platform aligns with industry trends towards point-of-care and at-home testing solutions, but the company's reliance on external financing and the widening net loss highlight the competitive pressures and capital intensity of this sector.

Comparison to Industry Standards

• The company's revenue of $0.15 million for the quarter is significantly lower than established diagnostic companies that have diversified product lines and broader market penetration.
• The net loss of $9.14 million, while a concern, is not uncommon for early-stage or development-focused diagnostic companies investing heavily in R&D and regulatory pathways.
• The company's strategy to pivot to a multiplexed respiratory test (ABCR) aligns with market demand seen from competitors like Luminex (now DiaSorin) and Bio-Rad Laboratories, which offer similar multiplex panels for infectious diseases.
• The withdrawal of the 510(k) submission for the COVID-19 test and subsequent focus on the ABCR test is a common occurrence in the FDA approval process, where companies must adapt to regulatory feedback and market shifts, a challenge faced by many in the diagnostics industry.

Legal Proceedings

• The company is a defendant in a class action suit alleging overstatement of demand for its Logix Smart COVID-19 test.
• The company is also a party to a civil action based on breach of contract claims.
• The company received a favorable ruling in its litigation with Hukui Technology, Inc.
• The company entered into a settlement agreement with Pantheon International Advisors Ltd. for $140,000 to resolve all disputes.

Related Party Transactions

• The company has a services agreement with CoSara Diagnostics Pvt Ltd, an equity method investment, for research and development consulting and support services. Expenses recognized were $226,396 for Q1 2026 and $240,103 for Q1 2025.

Stakeholder Impact

• Shareholders may experience dilution if additional equity financing is pursued.
• The widening net loss and going concern uncertainty could negatively impact investor confidence.
• Customers are impacted by the delay in the availability of the Co-Dx PCR platform for point-of-care and at-home use.
• Suppliers may face payment uncertainties if the company cannot secure adequate financing.

Next Steps

• Complete clinical performance studies for the Co-Dx PCR Flu A/B, COVID-19, RSV multiplex test (ABCR).
• Seek necessary regulatory approvals for the Co-Dx PCR platform.
• Explore additional equity and/or debt financing to fund operations and strategic opportunities.
• File a new registration statement if the company wishes to continue offering shares under an ATM program after the expiration of the previous one.

Key Dates

Recommendation

The company shows some revenue growth and has secured financing, but the significant increase in net loss, substantial R&D investment without immediate returns, and the ongoing going concern issue warrant a cautious approach. The pivot to a multiplexed test is strategically sound but introduces further development and regulatory hurdles. Investors should monitor progress on regulatory approvals and financing efforts.

Keywords

Co-Diagnostics, CODX, 10-Q, Quarterly Report, Molecular Diagnostics, PCR Platform, COVID-19 Test, Financial Results, Net Loss, R&D Expenses, Going Concern, FDA, Regulatory Approval